COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.
Adult
Aged
Aged, 80 and over
Autoimmune Diseases
/ mortality
COVID-19
/ immunology
Cohort Studies
Female
Hospitalization
/ statistics & numerical data
Humans
Influenza, Human
/ immunology
Male
Middle Aged
Prevalence
Prognosis
Republic of Korea
/ epidemiology
SARS-CoV-2
Spain
/ epidemiology
United States
/ epidemiology
Young Adult
COVID-19
Observational Health Data Sciences and Informatics (OHDSI)
Observational Medical Outcomes Partnership (OMOP)
autoimmune condition
hospitalization
mortality
open science
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
09 10 2021
09 10 2021
Historique:
received:
10
12
2020
accepted:
07
03
2021
pubmed:
17
3
2021
medline:
21
10
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization. We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%). Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.
Identifiants
pubmed: 33725121
pii: 6174122
doi: 10.1093/rheumatology/keab250
pmc: PMC7989171
doi:
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
SI37-SI50Subventions
Organisme : NLM NIH HHS
ID : R01 LM006910
Pays : United States
Organisme : Versus Arthritis
ID : 21605
Pays : United Kingdom
Organisme : NIH HHS
Pays : United States
Organisme : NIDDK NIH HHS
Pays : United States
Organisme : NHLBI NIH HHS
Pays : United States
Organisme : NLM NIH HHS
ID : T15 LM007079
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
Arthritis Rheumatol. 2021 Jun;73(6):914-920
pubmed: 33305544
Travel Med Infect Dis. 2020 Sep - Oct;37:101825
pubmed: 32763496
J Am Med Inform Assoc. 2015 May;22(3):553-64
pubmed: 25670757
J Gen Intern Med. 2021 Jun;36(6):1689-1695
pubmed: 33738759
J Thromb Thrombolysis. 2014 Oct;38(3):306-13
pubmed: 24464552
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Ann Rheum Dis. 2020 Jun;79(6):837-839
pubmed: 32332072
Int J Surg. 2020 May;77:206-216
pubmed: 32289472
N Engl J Med. 2020 Jul 2;383(1):85-88
pubmed: 32348641
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Intern Emerg Med. 2020 Nov;15(8):1375-1387
pubmed: 32653981
Ann Rheum Dis. 2020 Nov;79(11):1393-1399
pubmed: 32769150
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Autoimmun Rev. 2013 Aug;12(10):1004-15
pubmed: 23541482
BMC Med. 2011 Jan 10;9:1
pubmed: 21219637
Int J Rheum Dis. 2020 Jun;23(6):717-722
pubmed: 32462761
J Korean Med Sci. 2017 May;32(5):718-728
pubmed: 28378543
Nat Commun. 2020 Oct 6;11(1):5009
pubmed: 33024121
Rheumatol Int. 2020 Sep;40(9):1353-1360
pubmed: 32654078
Int J Obes (Lond). 2021 Jul 15;:
pubmed: 34267326
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Am J Cardiovasc Dis. 2012;2(3):171-83
pubmed: 22937487
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Rheum Dis. 2020 Sep;79(9):1163-1169
pubmed: 32546598
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Ann Rheum Dis. 2021 Jan 15;:
pubmed: 33452000
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2009 Feb;8(4):281-6
pubmed: 18817899
Inform Prim Care. 2011;19(3):135-45
pubmed: 22688222
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7329-36
pubmed: 27274072